antibiot
resist
ar
epidem
increas
magnitud
requir
rapid
identif
profil
appropri
time
therapeut
measur
contain
strategi
context
ciprofloxacin
part
firstlin
countermeasur
numer
high
consequ
bacteria
signific
resist
occur
via
singl
nucleotid
polymorph
snp
delet
within
ciprofloxacin
target
gene
ideal
use
ciprofloxacin
would
prefac
ar
determin
avoid
overus
misus
antibiot
describ
develop
evalu
panel
singlestrand
molecular
invers
probe
mip
coupl
nextgener
sequenc
ng
detect
genet
variant
known
confer
ciprofloxacin
resist
bacillu
anthraci
yersinia
pesti
francisella
tularensi
sequenc
result
demonstr
mip
captur
amplifi
target
region
interest
signific
level
coverag
depend
genet
variant
limit
detect
lod
highthroughput
pool
sequenc
rang
approxim
input
genom
copi
lod
increas
presenc
contamin
human
genom
dna
addit
show
mip
use
enrich
step
high
resolut
melt
hrm
realtim
pcr
sensit
assay
rapid
timetoansw
overal
technolog
multiplex
upfront
enrich
applic
multipl
downstream
molecular
assay
detect
target
genet
region
million
peopl
unit
state
succumb
antibiot
resist
ar
infect
annual
ad
signific
fiscal
burden
healthcar
system
due
prolong
treatment
extend
hospit
stay
increas
mortal
rate
emerg
organ
carbapenemresist
enterobacteriacea
vancomycinresist
enterococcu
drugresist
neisseria
gonorrhoea
highlight
need
effici
measur
diagnos
treat
ar
organ
measur
would
help
stop
transmiss
well
evolut
futur
multidrugresist
strain
better
antibiot
stewardship
better
diagnost
even
critic
address
biothreat
agent
inadvert
creation
resist
organ
overus
antibiot
could
dire
consequ
ciprofloxacin
member
quinolon
famili
antibiot
drug
firstlin
therapi
numer
bacteri
pathogen
includ
high
consequ
biothreat
agent
ciprofloxacin
target
bacteri
type
ii
topoisomeras
dna
gyras
topoisomeras
iv
coval
linkag
conserv
site
enzym
term
quinoloneresist
determin
region
qrdr
result
perman
doubl
strand
break
cell
death
highli
effect
suscept
bacteria
high
level
drug
resist
readili
acquir
genet
variant
target
gene
addit
fluoroquinolon
resist
also
result
decreas
drug
accumul
porin
loss
overexpress
efflux
pump
high
consequ
pathogen
bacillu
anthraci
yersinia
pesti
francisella
tularensi
natur
resist
ciprofloxacin
howev
serial
passag
organ
presenc
ciprofloxacin
quickli
result
mutat
qrdr
confer
highlevel
resist
diagnost
tool
identifi
qrdr
genet
variant
essenti
time
appropri
therapeut
measur
well
manag
spread
drugresist
bacteria
ideal
diagnost
rapid
sensit
inexpens
provid
inform
straintyp
virul
predict
ar
profil
compar
current
molecular
diagnost
realtim
pcr
nextgener
sequenc
ng
potenti
better
fulfil
requir
provid
inform
beyond
ident
etiolog
agent
includ
speci
level
identif
resist
profil
genom
epidemiolog
microbi
forens
current
unbias
metagenom
studi
expens
bioinformat
challeng
poor
clinic
sensit
target
sequenc
amplif
strategi
potenti
mitig
challeng
previou
studi
use
techniqu
padlock
molecular
invers
probe
mip
upfront
enrich
step
use
ng
show
specif
multiplex
techniqu
context
gapfil
molecular
invers
probe
combin
ng
allow
captur
evalu
substanti
genet
inform
specif
gap
fill
probe
circular
polymeras
ligas
captur
sequenc
amplifi
univers
primer
pair
prepar
ng
fig
recent
evalu
mip
platform
strain
type
extend
spectrum
betalactamas
produc
escherichia
coli
correl
well
current
diagnost
standard
amplifi
fragment
length
polymorph
techniqu
similarli
studi
show
mip
capabl
detect
distinguish
filoviru
speci
broad
pathogen
screen
biosurveil
character
use
mip
upfront
enrich
step
detect
genet
variant
confer
ciprofloxacin
resist
high
consequ
pathogen
b
anthraci
pesti
f
tularensi
use
ng
high
resolut
melt
hrm
realtim
pcr
downstream
molecular
detect
technolog
mutat
result
ciprofloxacin
resist
occur
qrdr
gene
encod
dna
gyras
topoisomeras
iv
test
viabil
mip
strategi
ciprofloxacin
resist
detect
design
complimentari
probe
arm
supplementari
tabl
flank
known
sequenc
variant
caus
resist
biothreat
agent
b
anthraci
anr
pesti
f
tularensi
assay
perform
assess
pool
probe
use
whole
genom
amplifi
wga
dna
wildtyp
strain
test
across
broad
rang
input
dna
concentr
superimpos
sequenc
read
refer
gene
probe
arm
demonstr
depth
coverag
target
region
interest
fig
sequenc
read
map
six
target
qrdr
refer
gene
plot
total
number
genom
copi
calcul
dna
input
concentr
demonstr
sigmoid
doserespons
linear
rang
begin
around
genom
copi
gene
map
fig
often
pool
ng
run
dualindex
sequenc
read
misidentifi
demultiplex
result
incorrect
read
map
sampl
known
sampl
bleed
account
misidentifi
read
nontempl
control
use
defin
background
term
throughout
paper
cutoff
cutoff
determin
averag
number
sequenc
read
map
refer
gene
nontempl
control
plu
three
time
standard
deviat
pearson
coeffici
demonstr
high
degre
correl
target
region
suggest
similar
captur
effici
supplementari
tabl
total
map
read
composit
shown
percentag
map
read
refer
gene
indic
decreas
total
input
dna
result
decreas
correctli
map
read
fig
cutoff
assay
sequenc
read
map
correctli
sequenc
read
cutoff
remain
unmap
refer
target
supplementari
figur
inde
cutoff
low
percentag
total
sequenc
read
map
refer
gene
gradual
increas
total
read
higher
input
concentr
supplementari
figur
analyt
limit
detect
lod
perform
confirm
captur
target
gene
demonstr
preliminari
cutoff
map
read
background
level
wild
type
cultur
howev
intend
applic
probe
detect
ciprofloxacin
resist
mutat
test
sequenc
coverag
target
genet
variant
assess
strain
mutat
known
confer
resist
ciprofloxacin
wga
may
incorpor
bia
experi
use
nonamplifi
whole
genom
extract
dna
accur
determin
assay
lod
linear
regress
util
fit
data
line
determin
point
genet
variant
read
coverag
cutoff
determin
nontempl
control
fig
cross
point
determin
assay
lod
lod
rang
given
genet
variant
base
standard
error
linear
regress
context
genet
variant
fell
within
rang
detect
input
genom
copi
similar
cutoff
level
determin
earlier
demonstr
previous
percentag
correctli
assign
read
concentr
near
lod
fig
diagnost
assay
requir
statist
reproduc
lod
clinic
applic
confirm
lod
perform
use
upper
lod
rang
demonstr
assay
reproduc
specif
analys
test
detect
b
anthraci
pesti
f
tularensi
genet
variant
total
input
genom
copi
respect
fig
across
replic
number
map
sequenc
read
demonstr
high
reproduc
experi
total
read
coverag
genet
variant
fall
near
coverag
line
replic
test
show
zero
coverag
given
locat
mock
clinic
perform
abil
detect
infecti
agent
directli
patient
sampl
essenti
evalu
new
diagnost
test
determin
assay
perform
broad
rang
input
genom
complex
sampl
matrix
isol
dna
whole
blood
spike
wga
bacteri
dna
mip
panel
test
sampl
demonstr
assay
perform
presenc
human
genom
directli
compar
result
previou
experi
number
input
genom
per
reaction
calcul
ng
dna
per
ml
blood
assum
extract
effici
sampl
process
fig
previous
describ
nontempl
control
use
determin
cutoff
valu
gene
number
input
genom
copi
requir
sequenc
read
background
approxim
higher
pure
bacteri
sampl
similar
analyt
analysi
person
correl
demonstr
signific
correl
target
region
suggest
similar
captur
effici
supplementari
tabl
high
resolut
melt
analysi
sequenc
data
show
target
amplif
coupl
ng
function
determin
ciprofloxacin
resist
confer
genet
variant
howev
ng
strategi
sacrific
cost
timetoansw
sensit
benefit
high
degre
target
multiplex
case
limit
sampl
volum
larg
number
potenti
target
realtim
pcr
hrm
realtim
pcr
screen
feasibl
multiplex
upfront
amplif
strategi
could
use
amplifi
target
interest
allow
screen
low
cost
quick
timetoansw
singleplex
assay
test
mip
applic
target
amplif
techniqu
molecular
assay
assess
hrm
assay
target
ciprofloxacin
resist
genet
variant
amplicon
gener
mip
protocol
detect
two
gyra
mutat
pare
delet
f
tularensi
use
mip
protocol
upfront
target
enrich
demonstr
differ
wildtyp
ciprofloxacin
resist
strain
fig
b
melt
peak
gyra
mutat
overal
decreas
melt
temperatur
pare
ttaaa
mutat
increas
melt
temp
due
increas
gc
content
furthermor
use
mip
significantli
amplifi
target
sequenc
base
cq
valu
hrm
experi
perform
purifi
genom
dna
versu
amplifi
mip
dna
fig
specif
mip
significantli
reduc
detect
background
hrm
analysi
even
dilut
mip
amplifi
materi
requir
assay
fall
within
optim
cq
rang
fig
overal
cumul
dataset
mip
suggest
techniqu
highli
multiplex
captur
system
util
multipl
molecular
detect
assay
genet
variant
identif
discuss
bacteri
organ
frequent
evolv
innat
immun
antibiot
surviv
environment
competit
nich
recent
howev
ecolog
studi
shown
develop
antibiot
resist
bacteri
pathogen
caus
increas
antibiot
usag
anim
food
human
continu
cycl
newli
acquir
resist
result
acquisit
genet
materi
genet
variat
organ
genom
current
standard
ar
suscept
test
labori
lengthi
process
requir
pure
bacteri
cultur
isol
patient
sampl
grown
presenc
antibiot
suscept
test
like
remain
realtim
pcr
current
standard
molecular
diagnost
pathogen
detect
recent
use
ar
profil
although
ng
quickli
adopt
clinic
laboratori
realtim
pcr
advantag
molecular
diagnost
mani
aspect
includ
cost
time
answer
sensit
one
major
aspect
time
answer
assay
sensit
abil
detect
pathogen
directli
patient
sampl
without
necess
cultur
bacteremia
septic
patient
rang
although
coloni
form
unitsml
blood
common
realtim
pcr
offer
sensit
approach
one
target
copi
per
reaction
allow
sampl
process
detect
directli
patient
sampl
ng
capabl
outpac
moor
law
boast
continu
technic
improv
past
decad
howev
rel
realtim
pcr
diagnost
sensit
still
lack
metagenom
sequenc
clinic
sampl
requir
ultradeep
sequenc
obtain
desir
coverag
level
target
pathogen
practic
routin
clinic
use
due
cost
informat
burden
target
sequenc
help
bridg
gap
sensit
seen
realtim
pcr
quantit
data
associ
ng
analyt
lod
mip
upfront
amplif
strategi
ng
fell
within
rang
approxim
input
genom
copi
mock
clinic
sampl
requir
approxim
greater
number
genom
copi
posit
detect
background
level
differ
like
attribut
carryov
inhibitor
complex
matric
variabl
effici
sampl
process
method
known
affect
pcr
lod
factor
affect
lod
includ
poor
signal
nois
misidentif
pool
sampl
specif
excess
mip
backbon
within
sampl
result
higher
nois
low
sampl
input
concentr
supplement
figur
de
novo
assembl
unmap
read
show
residu
mip
backbon
present
cleanup
due
format
concatem
amplif
process
result
background
problemat
input
concentr
approach
background
cutoff
similarli
incorrect
assign
dual
index
sampl
sampl
bleed
pronounc
lower
input
concentr
valu
percentag
correctli
map
read
drop
captur
region
test
read
misidentif
inher
limit
multiplex
ng
technolog
improv
overcom
sensit
realtim
pcr
still
suffer
inabl
significantli
multiplex
reaction
problemat
unknown
sampl
would
requir
numer
screen
identif
feasibl
limit
patient
sampl
volum
exacerb
regard
ar
multifacet
involv
enzym
pump
genet
variat
requir
multipl
target
identif
metagenom
sequenc
could
classifi
organ
along
known
resist
marker
howev
expertis
comput
infrastructur
requir
analyz
data
still
burdensom
clinic
biosurveil
program
metagenom
sequenc
conduc
pool
sampl
ng
run
due
difficulti
obtain
adequ
sequenc
coverag
genet
variant
complex
matric
increas
per
sampl
cost
depend
ng
instrument
ultradeep
sequenc
requir
run
time
rang
day
week
depend
desir
coverag
target
sequenc
allow
signific
coverag
desir
region
background
genom
simpl
refer
base
map
permit
sampl
pool
result
signific
cost
reduct
sequenc
result
hour
depend
desir
amplicon
length
cost
burden
mip
upfront
amplif
technolog
margin
increas
ng
librari
prepar
time
approxim
hour
slightli
longer
multiplex
pcr
base
amplif
technolog
requir
prior
knowledg
concern
input
etiolog
agent
desir
target
region
probe
design
inher
caveat
target
sequenc
approach
howev
new
outbreak
ebola
viru
new
resist
hospit
acquir
infect
like
carbapenemresist
enterobacteriacea
least
represent
within
public
sequenc
repositori
even
complet
novel
pathogen
sar
coronaviru
predic
within
phylogeni
allow
taxonom
placement
base
target
genom
sequenc
bacteri
identif
specif
ribosom
rna
use
classifi
organ
decad
conserv
dna
stretch
flank
hypervari
region
use
pcr
amplif
could
adapt
mip
pathogen
identif
probe
along
viral
specif
target
would
cover
signific
percentag
human
specif
pathogen
new
probe
due
multiplex
capabl
mip
design
complet
novel
organ
classifi
whole
genom
sequenc
effici
specif
reproduc
multiplex
captur
enrich
dna
region
within
organ
well
across
divers
speci
import
part
diagnost
biosurveil
panel
target
ng
techniqu
high
level
multiplex
pcr
often
reduc
specif
highli
multiplex
due
nonspecif
amplif
result
interact
primer
pair
target
circular
techniqu
mip
increas
specif
attribut
dual
enzymat
event
requir
gap
fill
ligat
exonucleas
digest
noncircular
materi
common
backbon
physic
restrict
two
homolog
bind
arm
sequenc
data
shown
demonstr
ciprofloxacin
mip
assay
captur
target
region
interest
within
organ
specif
reproduc
high
degre
multiplex
fact
pearson
coeffici
intraorgan
multiplex
captur
target
region
b
anthraci
f
tularensi
show
high
degre
correl
supplementari
tabl
similarli
correl
analysi
interorgan
probe
six
captur
region
highli
relat
reproduc
among
experi
high
degre
correl
suggest
multiplex
probeset
reproduc
captur
region
interest
similar
effici
across
broad
rang
input
dna
diagnost
applic
mip
sole
limit
ng
mip
also
serv
gener
enrich
strategi
molecular
detect
technolog
previous
publish
hrm
realtim
pcr
probe
captur
approxim
base
pair
genet
inform
allow
quick
identif
presenc
absenc
known
genet
variant
later
character
higher
granular
via
ng
potenti
resist
confer
element
triag
approach
becom
particularli
vital
patient
sampl
volum
restrict
therebi
limit
applic
multipl
molecular
diagnost
assay
nonmultiplex
screen
techniqu
mip
repres
overarch
multiplex
amplif
technolog
amen
ng
technolog
downstream
molecular
diagnost
techniqu
allow
potenti
diagnost
applic
includ
organ
classif
gene
identif
genet
variant
detect
name
strain
use
dna
prepar
bacteri
strain
use
studi
includ
wildtyp
ciprofloxacin
resist
bacillu
anthraci
anr
yersinia
pesti
francisella
tularensi
b
anthraci
wildtyp
ciprofloxacin
resist
mutant
clone
origin
obtain
dr
lanc
b
price
pesti
wildtyp
ciprofloxacin
resist
mutant
clone
origin
obtain
dr
luther
lindler
f
tularensi
wildtyp
ciprofloxacin
resist
mutant
obtain
dr
david
kulesh
dna
extract
purifi
use
qiagen
kit
qiagen
valencia
ca
accord
manufactur
instruct
fig
wga
dna
use
wga
perform
util
qiagen
repligmidi
kit
accord
manufactur
protocol
fig
g
wga
dna
spike
ml
whole
blood
bioreclamationivt
baltimor
md
fold
serial
dilut
l
dilut
extract
use
trizol
ls
thermo
fisher
scientif
waltham
qiagen
accord
manufactur
instruct
nontempl
control
water
fig
nonspik
extract
whole
blood
use
lieu
bacteri
dna
dna
concentr
quantifi
util
qubit
dsdna
br
hs
assay
kit
thermo
fisher
scientif
bacteri
mip
probe
analysi
probe
resuspend
buffer
te
pool
final
per
probe
concentr
nm
total
probe
combin
use
master
probe
mix
probe
captur
protocol
perform
previous
describ
slight
modif
modifi
protocol
follow
total
probe
mix
hybrid
serial
dilut
wga
nonamplifi
extract
dna
sampl
see
b
anthraci
pesti
f
tularensi
ad
nm
probe
ampligas
buffer
epicentr
madison
wi
heat
minut
ramp
temperatur
decreas
min
hold
gap
fill
ligat
perform
addit
phusion
highfidel
pcr
master
mix
hf
buffer
new
england
biolab
ipswich
unit
ampligas
epicentr
ampligas
buffer
dntp
biofir
salt
lake
citi
ut
reaction
incub
min
held
noncircular
dna
remov
exonucleas
exonucleas
iii
digest
specif
reaction
heat
min
held
unit
exonucleas
unit
exonucleas
iii
ad
sampl
incub
min
follow
enzymat
inactiv
min
captur
sequenc
amplifi
addit
platinum
taq
thermo
fisher
scientif
forward
cagatgttatgctcgcaggtc
revers
ggaacgatgagcctccaac
primer
buffer
mgcl
dntp
reaction
amplifi
min
cycl
sec
sec
min
hold
min
follow
amplif
sampl
purifi
util
agencourt
ampur
xp
bead
beckman
coulter
pasadena
ca
per
manufactur
protocol
slight
alter
mixtur
bead
sampl
volum
sequenc
analysi
librari
prepar
perform
apollo
system
wafergen
biosystem
fremont
ca
util
prepx
ilm
dna
librari
kit
wafergen
biosystem
truseq
dual
index
illumina
san
diego
ca
accord
manufactur
instruct
sampl
enrich
truseq
ht
prepar
kit
illumina
purifi
describ
sampl
quantifi
qubit
dsdna
br
hs
assay
kit
thermo
fisher
scientif
pool
base
total
concentr
proper
adaptor
ligat
confirm
final
normal
perform
use
kapa
librari
quantif
kit
kapa
biosystem
wilmington
amplicon
sequenc
use
miseq
platform
illumina
use
cycl
sequenc
kit
sequenc
read
analyz
use
clc
genom
workbench
clc
bio
cambridg
read
trim
qualiti
univers
primer
sequenc
use
filter
proper
captur
sequenc
trim
filter
read
map
known
refer
gene
includ
b
anthraci
ame
gyra
gyrb
parc
genbank
pesti
gyra
genbank
f
tularensi
gyra
pare
genbank
standard
set
read
map
use
requir
read
length
match
refer
least
ident
ignor
nonspecif
read
map
posit
hit
nontempl
control
run
concurr
measur
sampl
bleed
occur
sequenc
read
misidentifi
demultiplex
process
cutoff
determin
averag
number
sequenc
read
map
refer
gene
nontempl
control
plu
three
time
standard
deviat
coverag
repres
point
time
read
coverag
cutoff
control
lod
determin
base
defin
read
coverag
indic
genet
variant
variant
analysi
perform
map
sequenc
read
use
minimum
read
coverag
minimum
variant
frequenc
linear
regress
pearson
correl
perform
use
graphpad
prism
v
graph
softwar
graphpad
la
jolla
ca
high
resolut
melt
assay
amplicon
result
mip
captur
protocol
fig
ng
librari
prepar
use
templat
dilut
highresolut
melt
analysi
compar
concentr
genom
dna
use
input
mip
protocol
hplc
purifi
primer
f
tularensi
gyra
forward
cggtaaatatcaccctcatggag
revers
aggttgtgccattctgacaatagtat
pare
forward
cttacatggcattttgaaactggac
revers
cagcttctagtttatggtcaagatagcc
util
